Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT06006416
Other study ID # FENGUT
Secondary ID
Status Withdrawn
Phase Phase 3
First received
Last updated
Start date September 1, 2023
Est. completion date September 1, 2024

Study information

Verified date November 2023
Source RDC Clinical Pty Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A open label, self-controlled trial to evaluate the effect of Fenugreek Fibre (Trigonella foenum-graecum) on the gut microbiome in generally healthy adults aged 18-65 years old.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date September 1, 2024
Est. primary completion date May 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Male and females aged 18-65 years old - Generally healthy - Able to provide informed consent - BMI > 25kg/m2 - Agree not to participate in another clinical trial while enrolled in this trial - Agree not the change their diet or exercise while enrolled in this trial Exclusion Criteria: - Unstable(1) or serious illness (e.g. kidney, liver, GIT, heart conditions, diabetes, thyroid gland function, lung conditions, chronic asthma and mood disorders or neurological disorders such as MS) - Current malignancy (excluding BCC) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years - Currently taking Coumadin (Warfarin), Heparin, Dalteparin, Enoxaparin or other anticoagulation therapy - Acute sickness experienced within the past 2 months - Current use of medications (e.g. antibiotics) or supplements (e.g. pre- and probiotics) that alter the microbiome or gut health. Any use during the trial will result in exclusion from the study. - Active smokers and/or nicotine or drug abuse - Chronic alcohol use (>14 alcoholic drinks week) - Allergic to any of the ingredients in the formula - Pregnant(2) or lactating woman - Females of child bearing potential not using a highly effective form of contraception(3,4) (i.e. methods which result in low failure rate, i.e. less than 1% per year, when used consistently and correctly like the oral contraception pill, birth control implant e.g. implanon(3,4)) - People medically prescribed medications that would affect the immune and/or the inflammatory response (e.g. NSAIDs, steroids, antibiotics). - Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion - Participants who have participated in any other related clinical study during the past 1 month - People with cognitive damage - People who have or have had treatment for cancer, HIV or chronic use of any dose of steroids (cream, tablet or inhalant) in the past year Footnotes 1. An unstable illness is any illness that is currently not being treated with a stable dose of medication or is fluctuating in severity. A serious illness is a condition that carries a risk of mortality, negatively impacts quality of life and daily function and/or is burdensome in symptoms and/or treatments. 2. All female participants of child bearing potential will be required to take a urine pregnancy test prior to entry into the study. 3. Examples of acceptable forms of highly effective contraception include: Established use of oral, injected or implanted hormonal methods of contraception; Placement of an intrauterine device (IUD) or intrauterine system (IUS); Sterilised male partner (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate); True abstinence: When this is in line with your preferred and usual lifestyle 4. Examples of non-acceptable methods of contraception include: Condoms alone or double barrier; Periodic abstinence (e.g. calendar, ovulation, symptothermal, post ovulation); Withdrawal; Spermicide (as it is not approved as a method of contraception in Australia)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Fenugreek Fibre
Daily dose of 2 x 10g per day with/in food

Locations

Country Name City State
Australia RDC Global Pty Ltd Brisbane Queensland

Sponsors (1)

Lead Sponsor Collaborator
RDC Clinical Pty Ltd

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in metagenomic profile of the gut microbiome Change in metagenomic profile of the gut microbiome as measured by 16s rRNA gene sequencing Week 0, week 4 and week 16
Secondary Change in gut function Change in gut function as measured by faecal short change fatty acids testing via faecal sample Week 0, week 4 and week 16
Secondary Change in intestinal permeability Change in intestinal permeability as measured by plasma occludin, Muc2 and Endotoxin via blood test Week, 0, week 4, week 8 and week 16
Secondary Change in gut inflammation Change in gut inflammation as measured by faecal calprotectin via faecal sample Week 0, week 4 and week 16
Secondary Change in inflammation Change in inflammation as measured by inflammatory markers (IFN-g, TNF-a, il-2, MCP-2, IL-1b, TGF-b, CRP) via blood test Week, 0, week 4, week 8 and week 16
Secondary Change in GLP-1 Change in GLP-1 as measured by blood test Week, 0, week 4, week 8 and week 16
Secondary Change in GST Change in GST as measured by blood test Week, 0, week 4, week 8 and week 16
Secondary Change in glutathione Change in glutathione as measured by blood test Week, 0, week 4, week 8 and week 16
Secondary Change in FABP Change in FABP as measured by blood test Week, 0, week 4, week 8 and week 16
Secondary Change in Homocysteine Change in Homocysteine as measured by blood test Week, 0, week 4, week 8 and week 16
Secondary Change in diet Change in diet as measured by 24hr Dietary Recall Week 0 and Week 16 (completed for 3 consecutive days)
Secondary Change in quality of life Change in quality of life as measured by the SF-36 questionnaire. Consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. Week, 0, week 4, week 8 and week 16
Secondary Change in stress state Change in stress as measured by the Perceived Stress Scale questionnaire. Consists of 10 items with a score range 0-40. Higher scores indicate higher perceived stress. Week, 0, week 4, week 8 and week 16
Secondary Change in sleep quality Change in sleep as measured by the Leeds Sleep Evaluation Questionnaire. Consists of ten questions pertaining to four consecutive aspects of sleep: getting to sleep (GTS), quality of sleep (QOS), awakening from sleep (AFS), and behaviour following wakefulness (BFW). Higher scores indicate better sleep quality. Week, 0, week 4, week 8 and week 16
Secondary Change in safety Change in safety as measured by E/LFT via blood test Week 0, week 4 and week 16
Secondary Height Height as measured by stadiometer Week 0, week 4 and week 16
Secondary Change in weight Change in weight as measured by digital scale Week 0, week 4 and week 16
Secondary Change in hip and weight circumference Change in hip and weight circumference as measured by tape measure Week 0, week 4 and week 16
Secondary Change in blood pressure Change in blood pressure as measured by blood pressure monitor Week 0, week 4 and week 16
See also
  Status Clinical Trial Phase
Recruiting NCT05793112 - INF108F in Infants With Food Protein Induced Proctocolitis Phase 4
Active, not recruiting NCT04327141 - Low Sugar Protein Pacing, Intermittent Fasting Diet in Men and Women N/A
Recruiting NCT04117321 - Mother-infant Microbiota Transmission and Its Link to the Health of the Baby
Recruiting NCT05655910 - Enhanced Nutritional Optimization in LVAD Trial N/A
Recruiting NCT03325855 - Fecal Microbiota Transplant National Registry
Active, not recruiting NCT05931471 - Yogurt and GI Health N/A
Recruiting NCT03797417 - Gut Microbiome and Metabolic Pathways Changes in Vitiligo
Recruiting NCT06206486 - The Gut Microbiome and Serum Metabolites as a Biological Mechanism Underlying Pain in Kidney Transplantation
Completed NCT02655250 - Neonatal Microbiome Validity Study
Recruiting NCT05670288 - Impact of Gut Microbiome on Metabolic and Bowel Function During the First Year After Spinal Cord Injury
Not yet recruiting NCT03975764 - Fecal Microbiota in Preterm Birth
Completed NCT03219931 - NEOBIFI: Clinical Trial for the Prevention and/or Reduction of the Incidence of Colics in Infants Phase 4
Recruiting NCT04447365 - The Correlation Between Gut Microbiome-host Interaction and Ventricular Arrhythmias.
Recruiting NCT04466072 - Gut Microbiome and Ventricular Arrhythmias
Not yet recruiting NCT06130137 - Gut Microbiome in People Living With HIV and HBV
Recruiting NCT06260579 - Home-based Exercise and Physical Activity Intervention After Kidney Transplantation: Impact of Exercise Intensity N/A
Completed NCT04511052 - Probiotics for Enhanced Tissue Carotenoid Status in Premenopausal Women Phase 1/Phase 2
Active, not recruiting NCT06424691 - Infant Restore: Efficacy of Microbiome Analysis and Education N/A
Recruiting NCT06404749 - Fungal Fiber for Gut Health N/A
Not yet recruiting NCT06433310 - Understanding the Efficacy of Dietary Supplement on Fungal Mycobiota in Healthy Volunteers: A Pilot Study Early Phase 1